Medtronic Inc. announced the first patient enrollment in the WRAP Infection Clinical Trial, which will evaluate the effectiveness of the TYRX Absorbable Antibacterial Envelope in reducing major infections in patients with cardiac implantable electronic devices (CIEDs) at risk for infection.

In a rural Maine county, sustained community-wide programs targeting cardiovascular risk factors and behavior changes were associated with reductions in hospitalization and death rates over a 40-year period (1970-2010) compared with the rest of the state. Substantial improvements were seen in control of hypertension, cholesterol and smoking cessation, according to a study in the January 13 issue of the Journal of the American Medical Association (JAMA).

rivaroxaban, Xarelto, safety performance, Janssen, NVAF

A new post-marketing study evaluating the safety of once-daily rivaroxaban (Xarelto) shows, in patients with non-valvular atrial fibrillation (NVAF), rates and patterns of major bleeding in routine clinical practice are generally consistent with those observed in Phase 3 clinical trials used to approve the medicine for this indication. These 15-month results, published in Clinical Cardiology, represent initial findings from an ongoing, five-year observational study of patients using rivaroxaban daily over the course of their lives.

Sunshine Heart Inc. announced the company's German Erlangen site for the OPTIONS-HF study has implanted its first patient with the C-Pulse(R) System for moderate to severe heart failure. 

The America College of Cardiology has released its list of key late-breaking clinical trials at the ACC 2015 meeting in March. Here are my top picks for cardiovascular device technology I am looking forward to hearing data on: 

The number of IVC filters placed has more than doubled in the last 10 years, and by some estimates, less than half of these retrievable devices are actually removed each year.

ACC 2015 late breaking trials

The latest data on TAVR, transcatheter mitral valve repair, the use of CT to evaluate chest pain, first report on the use of TAVR embolic protection, denervation for pulmonary arterial hypertension, and outcomes with drug-eluting stents vs. bypass surgery. 

There could soon be new hope for those facing one of humanity's biggest health issues, thanks to research from the University of Tennessee Knoxville College of Engineering.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now